PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 12-08-2022
11.40 USD   +9.62%
04/08Protagonist Therapeutics, Inc. Rapporteert Winstresultaten voor het Tweede Kwartaal en de Zes Maanden Eindigend op 30 Juni, 2022
CI
26/05Protagonist Therapeutics, Inc. presenteert geactualiseerde Fase 2 Rusfertide klinische resultaten in Polycythemia Vera (PV) op ASCO 2022
CI
18/05PROTAGONIST THERAPEUTICS, INC. : Piper Sandler geeft koopadvies
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op PROTAGONIST THERAPEUTICS, INC.
05/08PROTAGONIST THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
05/08PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
04/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
04/08Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six ..
04/08PROTAGONIST THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Corp..
19/07Protagonist Therapeutics Reports Granting of Inducement Award
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000 Value Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2000 Growth Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2000 Value Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell Small Cap Comp Growth In..
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000 Growth Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2500 Value Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 3000E Value Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000E Growth Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell Microcap Growth Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Small Cap Comp Value Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2500 Growth Index
24/06PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Microcap Value Index
02/06PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form ..
01/06Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
26/05Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results i..
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
04/05PROTAGONIST THERAPEUTICS : Q1 Earnings Snapshot
04/05Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Mar..
26/04Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bo..
26/04Top Midday Decliners
26/04Top Premarket Decliners
26/04PROTAGONIST THERAPEUTICS : Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ul..
26/04PROTAGONIST THERAPEUTICS, INC : Financial Statements and Exhibits (form 8-K)
26/04TRANSCRIPT : Protagonist Therapeutics, Inc. - Special Call
25/04Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
25/04Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in U..
20/04PROTAGONIST THERAPEUTICS : Initial Statement of Beneficial Ownership (Form 3)
19/04Protagonist Therapeutics Reports Granting of Inducement Awards
14/04SECTOR UPDATE : Health Care Stocks Fading Late, Stop Just Shy of Higher Close
14/04Top Midday Decliners
14/04Protagonist Stock Tumbles Thursday as FDA Plans to Rescind Rusfertide Breakthrough Desi..
14/04SECTOR UPDATE : Health Care Stocks Edging Lower on Thursday
14/04SECTOR UPDATE : Health Care
14/04Wall Street Treads Water Pre-Bell; Jobless Claims Rise
14/04SECTOR UPDATE : Health Care Stocks Lean Lower Premarket Thursday
14/04SECTOR UPDATE : Health Care
14/04Top Premarket Decliners
14/04Protagonist Therapeutics Gets FDA Letter to Rescind Breakthrough Therapy Designation fo..
14/04Protagonist Shares Tumble After FDA Says It May Pull Rusfertide Breakthrough Designatio..
13/04Protagonist Therapeutics Gets FDA Letter to Rescind Breakthrough Therapy Designation fo..
13/04PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
13/04Protagonist Therapeutics, Inc. Expects to Announce Top-Line Data from Its Phase 2 Clini..
31/03PROTAGONIST THERAPEUTICS, INC : Change in Directors or Principal Officers (form 8-K)
28/03Protagonist Therapeutics Names Asif Ali Finance Chief
28/03Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President ..
28/03Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President ..
23/03PROTAGONIST THERAPEUTICS, INC : Change in Directors or Principal Officers (form 8-K)
23/03Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen as Principal Finan..
23/03Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen, Chief Financial O..
16/03Protagonist Therapeutics Gets $25 Million Milestone Payment from J&J's Janssen Biotech
16/03Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for D..
01/03PROTAGONIST THERAPEUTICS, INC Management's Discussion and Analysis of Financial Condit..
01/03PROTAGONIST THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and..
28/02PROTAGONIST THERAPEUTICS : Q4 Earnings Snapshot
28/02Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended Decembe..
28/02Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended De..
28/02Protagonist Therapeutics, Inc. Announces Pivotal Phase 3 VERIFY Study of Rusfertide in ..
22/02PROTAGONIST THERAPEUTICS, INC : Change in Directors or Principal Officers (form 8-K)
10/02Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Co..
11/01TRANSCRIPT : Protagonist Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Co..
04/01/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
2021INSIDER SELL : Protagonist Therapeutics
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
1  2  3  4  5  6  7Volgende
Volgende evenement op PROTAGONIST THERAPEUTICS, INC.